Lyn-analyse: Derfor investerer Genmab med stor risiko i hollandsk biotek

Genmab har annonceret, at man vil købe det hollandske biotekselskab Merus for 51 mia. kr. Hvis købet går i gennem bliver det danmarkshistoriens syvende største virksomhedsopkøb nogensinde. Alligevel er Genmabs aktiekurs i dag faldet med mere end 3 pct.  Gæst: Heidi Birgitte Nielsen, økonomiredaktør, Finans Vært: Kasper Søegaard, podcastredaktør, Finans See omnystudio.com/listener for privacy information.

Episode metadata supplied by the publisher feed · Published Sep 29, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Lyn-analyse: Derfor investerer Genmab med stor risiko i hollandsk biotek

0:00 5:16

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Finans Podcast?

This episode is 5 minutes long.

When was this Finans Podcast episode published?

This episode was published on September 29, 2025.

Can I download this Finans Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!